Carnosine for Peripheral Arterial Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Louisville, Louisville, KY
Peripheral Arterial Disease+1 More
Carnosine - Biological
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial suggests that L-carnosine supplements can improve the symptoms of peripheral artery disease. Carnosine is used to treat Peripheral Arterial Disease and has been approved by the FDA for a different condition. This treatment is free and no patients in this trial will receive a placebo.

Eligible Conditions

  • Peripheral Arterial Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Peripheral Arterial Disease

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: One year

One year
Carnosine for Peripheral Arterial Disease patients
one year
Graded treadmill test

Trial Safety

Safety Progress

1 of 3

Other trials for Peripheral Arterial Disease

Side Effects for

Carnosine Treatment Group
8%Costochondritis
8%Hypergammaglobulinemia
0%Elevated CRP Levels
This histogram enumerates side effects from a completed 2012 Phase 2 trial (NCT00810368) in the Carnosine Treatment Group ARM group. Side effects include: Costochondritis with 8%, Hypergammaglobulinemia with 8%, Elevated CRP Levels with 0%.

Trial Design

1 Treatment Group

Carnosine intervention for patients with PAD
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Carnosine · No Placebo Group · Phase 1 & 2

Carnosine intervention for patients with PAD
Biological
Experimental Group · 1 Intervention: Carnosine · Intervention Types: Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carnosine
2008
Completed Phase 2
~230

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: one year
Closest Location: University of Louisville · Louisville, KY
Photo of ky university of louisville 1Photo of ky university of louisville 2Photo of louisville 3
2017First Recorded Clinical Trial
6 TrialsResearching Peripheral Arterial Disease
301 CompletedClinical Trials

Who is running the clinical trial?

University of LouisvilleLead Sponsor
311 Previous Clinical Trials
73,587 Total Patients Enrolled
1 Trials studying Peripheral Arterial Disease
10 Patients Enrolled for Peripheral Arterial Disease

Eligibility Criteria

Age 18+ · Male Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a male subject aged at least 50 to less than 80 years.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References